Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients

Transplantation

Volumn 93, Issue 5, 2012, Pages 536-542

  Abate, Davide ^a   Cesaro, Simone ^a,b   Cofano, Simona ^a   Fiscon, Marta ^a   Saldan, Alda ^a   Varotto, Stefania ^a   Mengoli, Carlo ^a   Pillon, Marta ^a   Calore, Elisabetta ^a   Biasolo, Maria Angela ^a   Cusinato, Riccardo ^a   Barzon, Luisa ^a   Messina, Chiara ^a   Carli, Modesto ^a   Palù, Giorgio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

Antiviral immune reconstitution; Cytomegalovirus; ELISPOT; Pediatric hematopoietic stem cell transplantation; T cell immunity

Indexed keywords

CIDOFOVIR; CYTOMEGALOVIRUS ANTIBODY; FOSCARNET; GANCICLOVIR; STEROID;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CELLULAR IMMUNITY; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC VALUE; DONOR; ENZYME LINKED IMMUNOSPOT ASSAY; FANCONI ANEMIA; FEMALE; FEVER; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE RESPONSE; INFANT; JUVENILE MYELOMONOCYTIC LEUKEMIA; LEUKEMIA RELAPSE; MALE; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECIPIENT; SCHOOL CHILD; SEROLOGY; T LYMPHOCYTE; VIREMIA; VIRUS REACTIVATION;

ADOLESCENT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNITY, CELLULAR; INFANT; ITALY; KAPLAN-MEIER ESTIMATE; MALE; MONITORING, IMMUNOLOGIC; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; T-LYMPHOCYTES; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIREMIA;

EID: 84857645286     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31824215db     Document Type: Article

References (56)

1. Mocarski ES Jr, Courcelle CT. Cytomegaloviruses and their replication. In: Knipe DM, Howley PM, eds. Fields virology. Philadelphia, PA, Lippincott Williams & Wilkins 2001, p 2629.
2. Maury S, Mary JY, Rabian C, et al. Prolonged immune deficiency following allogeneic stem cell transplantation: Risk factors and complications in adult patients. Br J Haematol 2001;115:630.
3. Hebart H, Einsele H. Specific infectious complications after stem cell transplantation. Support Care Cancer 2004;12:80.
4. Ljungman P. CMV infections after hematopoietic stem cell transplantation. Bone Marrow Transplant 2008;42(suppl 1): S70.
5. Hebart H, Einsele H. Clinical aspects of CMV infection after stem cell transplantation. Hum Immunol 2004;65:432.
6. Pass RF. Cytomegalovirus. In: Knipe D, Howley P, eds. Fields virology. Philadelphia, PA, Lippincott Williams & Wilkins 2001, p. 2675.
7. Marty FM, Rubin RH. The prevention of infection post-transplant: The role of prophylaxis, preemptive and empiric therapy. Transpl Int 2006;19:2.
8. Zaia J, Baden L, Boeckh MJ, et al. Viral disease prevention after hematopoietic cell transplantation. Bone Marrow Transplant 2009;44:471.
9. Couriel D, Canosa J, Engler H, et al. Early reactivation of cytomegalovirus and high risk of interstitial pneumonitis following T-depleted BMT for adults with hematological malignancies. Bone Marrow Transplant 1996;18:347.
10. Patel SR, Ridwan RU, Ortin M. Cytomegalovirus reactivation in pediatric hemopoietic progenitors transplant: A retrospective study on the risk factors and the efficacy of treatment. J Pediatr Hematol Oncol 2005;27:411.
11. Hakki M, Riddell SR, Storek J, et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: Impact of host factors, drug therapy, and subclinical reactivation. Blood 2003;102:3060.
12. Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: Importance of viral load and T-cell immunity. Blood 2003;101:407.
13. Nichols WG, Corey L, Gooley T, et al. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: Evidence for indirect effects of primary CMV infection. J Infect Dis 2002;185:273.
14. Junghanss C, Boeckh M, Carter RA, et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 2002;99:1978.
15. Sinclair J, Sissons P. Latency and reactivation of human cytomegalovirus. J Gen Virol 2006;87(Pt 7):1763.
16. Hebart H, Daginik S, Stevanovic S, et al. Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-gamma-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation. Blood 2002;99:3830.
17. Boeckh M, Fries B, Nichols WG. Recent advances in the prevention of CMV infection and disease after hematopoietic stem cell transplantation. Pediatr Transplant 2004;8(suppl 5):19.
18. Goodrich JM, Bowden RA, Fisher L, et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993;118:173.
19. Li CR, Greenberg PD, Gilbert MJ, et al. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: Correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994;83:1971.
20. Kern F, Bunde T, Faulhaber N, et al. Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. J Infect Dis 2002;185:1709.
21. Maecker HT, Maino VC. Analyzing T-cell responses to cytomegalovirus by cytokine flow cytometry. Hum Immunol 2004;65:493.
22. Sylwester AW, Mitchell BL, Edgar JB, et al. Broadly targeted human cytomegalo virus-specific CD4+ and CD8+T cells dominate the memory compartments of exposed subjects. J Exp Med 2005;202:673.
23. Dunn HS, Haney DJ, Ghanekar SA, et al. Dynamics of CD4 and CD8 T cell responses to cytomegalovirus in healthy human donors. J Infect Dis 2002;186:15.
24. Gillespie GM, Wills MR, Appay V, et al. Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8 (+) T lymphocytes in healthy seropositive donors. J Virol 2000;74:8140.
25. Lilleri D, Gerna G, Fornara C, et al. Prospective simultaneous quantification of human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in young recipients of allogeneic hematopoietic stem cell transplants. Blood 2006;108:1406.
26. Pourgheysari B, Khan N, Best D, et al. The cytomegalovirus-specific CD4+T-cell response expands with age and markedly alters the CD4+ T-cell repertoire. J Virol 2007;81:7759.
27. Motta VN, Martins SL. Impairment of cytomegalovirus-specific cellular immune response as a risk factor for cytomegalovirus disease in transplant recipients. Braz J Med Biol Res 2008;41:5.
28. Gor D, Sabin C, Prentice HG, et al. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: Relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease. Bone Marrow Transplant 1998;21:597.
29. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986;153:478.
30. Grob JP, Grundy JE, Prentice HG, et al. Immune donors can protect marrow-transplant recipients from severe cytomegalovirus infections. Lancet 1987;1:774.
31. Ljungman P, Brand R, Einsele H, et al. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: An EBMT megafile analysis. Blood 2003;102:4255.
32. Ringden O, Schaffer M, Le Blanc K, et al. Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and-DRB1 genomically identical volunteers? Biol Blood Marrow Transplant 2004;10:128.
33. Gerna G, Lilleri D. Monitoring transplant patients for human cytomegalovirus: Diagnostic update. Herpes 2006;13:4.
34. Griffiths P, Whitley R, Snydman DR, et al. Contemporary management of cytomegalovirus infection in transplant recipients: Guidelines from an IHMF workshop, 2007. Herpes 2008;15:4.
35. Ljungman P. Would monitoring CMV immune responses allow improved control of CMV in stem cell transplant patients. J Clin Virol 2006;35:493.
36. Solano C, Benet I, Clari MA, et al. Enumeration of cytomegalovirusspecific interferongamma CD8+ and CD4+ T cells early after allogeneic stem cell transplantation may identify patients at risk of active cytomegalovirus infection. Haematologica 2008;93:1434.
37. Gratama JW, van Esser JW, Lamers CH, et al. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood 2001;98:1358.
38. Moss P, Khan N. CD8 (+) T-cell immunity to cytomegalovirus. Hum Immunol 2004;65:456.
39. Reusser P, Riddell SR, Meyers JD, et al. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: Pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991;78:1373.
40. Krause H, Hebart H, Jahn G, et al. Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease. Bone Marrow Transplant 1997;19:1111.
41. Aubert G, Hassan-Walker AF, Madrigal JA, et al. Cytomegalovirusspecific cellular immune responses and viremia in recipients of allogeneic stem cell transplants. J Infect Dis 2001;184:955.
42. Avetisyan G, Aschan J, Hagglund H, et al. Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT. Bone Marrow Transplant 2007;40:865.
43. Lacey SF, Diamond DJ, Zaia JA. Assessment of cellular immunity to human cytomegalovirus in recipients of allogeneic stem cell transplants. Biol Blood Marrow Transplant 2004;10:433.
44. Szabolcs P. T-lymphocyte recovery and function after cord blood transplantation. Immunol Res 2011;49:56.
45. Cesaro S, Murrone A, Mengoli C, et al. The real-time polymerase chain reaction-guided modulation of immunosuppression enables the preemptive management of Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2005;128:224.
46. Sullivan KM. Acute and chronic graft-vs.-host disease in man. Int J Cell Cloning 1986;4(suppl 1):42.
47. Bearman SI, Appelbaum FR, Buckner CD, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988;6:1562.
48. Calore E, Calo A, Tridello G, et al. Extracorporeal photochemotherapy may improve outcome in children with acute GVHD. Bone Marrow Transplant 2008;42:421.
49. Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009;113:5711.
50. Bordon V, Bravo S, Van Renterghem L, et al. Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: Incidence and outcome of CMV infection and disease. Transpl Infect Dis 2008;10:19.
51. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002;34:1094.
52. Reusser P, Einsele H, Lee J, et al. Randomized multicenter trial of foscarnet vs. ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 2002;99:1159.
53. Cesaro S, Zhou X, Manzardo C, et al. Cidofovir for cytomegalovirus reactivation in pediatric patients after hematopoietic stem cell transplantation. J Clin Virol 2005;34:129.
54. Karlsson AC, Martin JN, Younger SR, et al. Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells. J Immunol Methods 2003;283:141.
55. Asemissen AM, Nagorsen D, Keilholz U, et al. Flow cytometric determination of intracellular or secreted IFNgamma for the quantification of antigen reactive T cells. J Immunol Methods 2001;251:101.
56. Sun Y, Iglesias E, Samri A, et al. A systematic comparison of methods to measure HIV-1 specific CD8 T cells. J Immunol Methods 2003;272:23.